Eli Lilly Says Canada Skewing Facts In $354M IP Arbitration
By Christine Powell ( January 27, 2016, 7:26 PM EST) -- Eli Lilly has blasted the Canadian government's argument that a purported shift in the focus of its CA$500 million ($354 million) dispute over the country's cancellation of its patents for Strattera and Zyprexa stripped a World Bank tribunal of jurisdiction to hear its claims, according to arbitration documents made public Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.